Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Smruthi Organics Ltd (540686)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540686 NSE: Pharmaceuticals & Drugs | Small Cap | Smruthi Organics Share Price
₹126.95 -1.00 (-0.78%)
As on 13-Aug'26 16:59
Smruthi Organics Ltd (540686)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540686 NSE: Pharmaceuticals & Drugs | Small Cap | Smruthi Organics Share Price
₹126.95 -1.00 (-0.78%)
As on 13-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹145 Cr.
Current Price
₹127
52-Week Low / High
₹95 / 164
TTM EPS
₹6.5
TTM Sales
₹112 Cr.
Book Value per Share
₹66.8
P/E Ratio
19.47
Lower than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
1.90
Lower than its 5-year historical median
Price to Sales (P/S)
1.29
In line with its 5-year historical median
EV/EBITDA
8.10
Lower than its 5-year historical median
Dividend Yield
1.18%
Profitability Efficiency
Return on Equity (ROE)
4.72%
Underperforms industry median
Return on Capital Employed (ROCE)
7.46%
Underperforms industry median
Return on Assets (ROA)
3.14%
Operating Profit Margin
13%
Net Profit Margin
3.36%
Gross Profit Margin
11.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-19.08%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
7.24%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-3.65%
Asset Quality
Promoter Holding
64.73%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹65 Cr.
Equity
₹11.5 Cr.
Face Value
₹10
All Time Low / High
₹21.70 / 419.35
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Smruthi Organics Ltd a good quality company?
Smruthi Organics Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Smruthi Organics Ltd performance compare with that of its Peers?
Revenue growth of Smruthi Organics Ltd vs industry peers?
Smruthi Organics Ltd revenue CAGR is -4.22%, compared to the industry median CAGR of 5.68%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Smruthi Organics Ltd?
Promoters hold 64.73% of the Smruthi Organics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Smruthi Organics Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -18.91% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Smruthi Organics Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 10.6% | -1% | 21.5% | 25% | 39.1% | 21% | 7.4% | 8.2% | 8% | 7.5% | - |
| Value Creation Index ⓘ | -0.2 | -1.1 | 0.5 | 0.8 | 1.8 | 0.5 | -0.5 | -0.4 | -0.4 | -0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 79.4 | 97.3 | 137 | 131 | 127 | 133 | 141 | 128 | 126 | 102 | 112 |
| Sales YoY Gr. | - | 22.7% | 41.2% | -4.6% | -3.5% | 5.4% | 5.8% | -9.5% | -1.3% | -19.1% | - |
| Adj EPS ⓘ | 1.4 | -2.8 | 6 | 5.3 | 14.9 | 9.2 | 3.7 | 3.3 | 3.1 | 3.4 | 6.5 |
| YoY Gr. | - | -303.6% | NA | -12.3% | 183.5% | -38% | -60.1% | -11.9% | -4.6% | 10.7% | - |
| BVPS (₹) ⓘ | 28.2 | 25.4 | 31.8 | 37.1 | 52.9 | 58.7 | 59.6 | 60.8 | 62.6 | 64.2 | 66.8 |
| Adj Net Profit ⓘ | 1.6 | -3.2 | 6.9 | 6 | 17.1 | 10.6 | 4.2 | 3.7 | 3.6 | 3.9 | 7 |
| Cash Flow from Ops. ⓘ | 9.2 | 5.1 | 12.1 | 21.4 | 22.8 | 2.2 | 12.1 | 4.4 | 10 | 22.3 | - |
| Debt/CF from Ops. ⓘ | 3.5 | 6 | 2.3 | 0.7 | 0.4 | 1.3 | 0.5 | 2.7 | 1.7 | 0.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 2.8% | -4.2% | -10.3% | -19.1% | ||||
| Adj EPS ⓘ | 10.7% | -25.5% | -2.4% | 10.7% | ||||
| BVPSⓘ | 9.6% | 4% | 2.6% | 2.6% | ||||
| Share Price | - | -18.7% | -6.5% | 4.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5 | -10.5 | 21 | 15.3 | 33.1 | 16.6 | 6.2 | 5.4 | 5 | 5.4 | 10 |
| Op. Profit Mgn % ⓘ | 12.6 | 3.4 | 12.5 | 12.1 | 22.6 | 14 | 7 | 9.5 | 9.7 | 13 | 16.6 |
| Net Profit Mgn % ⓘ | 2 | -3.3 | 5 | 4.6 | 13.5 | 7.9 | 3 | 2.9 | 2.8 | 3.9 | 6.7 |
| Debt to Equity ⓘ | 1 | 1.1 | 0.8 | 0.4 | 0.2 | 0 | 0.1 | 0.2 | 0.2 | 0.1 | - |
| Working Cap Days ⓘ | 258 | 194 | 155 | 163 | 139 | 132 | 153 | 197 | 204 | 209 | 75 |
| Cash Conv. Cycle ⓘ | 90 | 80 | 66 | 58 | 48 | 81 | 92 | 99 | 119 | 134 | 40 |
Valuation of Smruthi Organics - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 97 | 137 | 131 | 127 | 133 | 141 | 128 | 126 | 102 |
| Operating Expenses ⓘ + | 69 | 94 | 121 | 116 | 98 | 115 | 131 | 116 | 114 | 89 |
| Operating Profit ⓘ | 10 | 3 | 17 | 15 | 29 | 18 | 10 | 12 | 12 | 13 |
| Operating Profit Margin (%) | 12.5% | 3.3% | 12.1% | 11.6% | 22.6% | 13.8% | 6.9% | 9.4% | 9.7% | 12.8% |
| Other Income ⓘ + | 1 | 0 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 0 |
| Interest ⓘ | 4 | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation ⓘ | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 6 |
| Profit Before Tax ⓘ | 3 | -5 | 10 | 12 | 24 | 14 | 4 | 5 | 5 | 5 |
| Tax ⓘ | 1 | -1 | 3 | 4 | 7 | 3 | 0 | 1 | 1 | 1 |
| Profit After Tax | 2 | -3 | 7 | 8 | 17 | 10 | 4 | 4 | 4 | 3 |
| PAT Margin (%) | 2.0% | -3.3% | 5.0% | 6.4% | 13.5% | 7.8% | 2.9% | 2.8% | 2.8% | 3.4% |
| Adjusted EPS (₹) | 1.4 | -2.8 | 6.0 | 7.4 | 15.0 | 9.1 | 3.6 | 3.1 | 3.1 | 3.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 11.10% | 13.60% | 20.10% | 33.10% | 55.40% | 47.80% | 48.20% | 50.10% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 32 | 29 | 36 | 42 | 60 | 67 | 68 | 70 | 72 | 74 | |
| Debt + | 27 | 29 | 28 | 16 | 10 | 3 | 5 | 10 | 14 | 8 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 17 | 22 | 30 | 22 | 14 | 11 | 25 | 29 | 16 | 14 | |
| Others Liabilities ⓘ | 10 | 4 | 7 | 7 | 7 | 7 | 9 | 11 | 11 | 9 | |
| Total Liabilities ⓘ | 85 | 84 | 101 | 88 | 92 | 88 | 107 | 119 | 113 | 105 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 30 | 30 | 30 | 32 | 31 | 33 | 37 | 40 | 45 | 47 | |
| CWIP ⓘ | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 3 | 3 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 19 | 21 | 23 | 17 | 18 | 20 | 24 | 30 | 28 | 28 | |
| Trade Receivables | 21 | 25 | 36 | 25 | 21 | 28 | 37 | 41 | 32 | 19 | |
| Cash Equivalents | 2 | 2 | 4 | 4 | 16 | 1 | 2 | 1 | 1 | 2 | |
| Others Assets ⓘ | 12 | 5 | 6 | 11 | 4 | 4 | 5 | 6 | 4 | 5 | |
| Total Assets ⓘ | 85 | 84 | 101 | 88 | 92 | 88 | 107 | 119 | 113 | 105 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 9 | 5 | 12 | 21 | 23 | 2 | 12 | 4 | 10 | 22 |
| Cash Flow From Investing Activity ⓘ + | -0 | -3 | -4 | -5 | -3 | 7 | -10 | -7 | -11 | -9 |
| Cash Flow From Financing Activity ⓘ + | -9 | -2 | -5 | -17 | -7 | -12 | -2 | 3 | 1 | -12 |
| Net Cash Flow ⓘ | 0 | 0 | 2 | -1 | 13 | -3 | 0 | -0 | -0 | 1 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 5.03 | -10.48 | 20.97 | 21.43 | 33.23 | 16.27 | 6.11 | 5.21 | 5.04 | 4.72 |
| ROCE (%) | 10.6 | -0.96 | 21.54 | 25 | 39.08 | 21 | 7.39 | 8.22 | 7.98 | 7.46 |
| Asset Turnover Ratio | 0.91 | 1.16 | 1.49 | 1.39 | 1.41 | 1.49 | 1.46 | 1.17 | 1.09 | 0.94 |
| PAT to CFO Conversion(x) | 4.5 | N/A | 1.71 | 2.63 | 1.35 | 0.2 | 3 | 1 | 2.5 | 7.33 |
| Working Capital Days | ||||||||||
| Receivable Days | 86.50 | 86.30 | 81.90 | 84.90 | 66.30 | 68.10 | 84.30 | 107.60 | 105.60 | 92 |
| Inventory Days | 83.10 | 75.50 | 58.10 | 55.40 | 50.80 | 52 | 56.60 | 74.20 | 83.50 | 100.70 |
| Payable Days | 117.20 | 114.40 | 103.70 | 113.80 | 99.40 | 57.10 | 71.30 | 134.40 | 118.70 | 119.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Smruthi Organics Ltd FAQs
The current trading price of Smruthi Organics on 13-Aug-2026 16:59 is ₹127.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Aug-2026 the market cap of Smruthi Organics stood at ₹145.3 Cr
The latest P/E ratio of Smruthi Organics as of 12-Aug-2026 is 19.47.
The latest P/B ratio of Smruthi Organics as of 12-Aug-2026 is 1.90.
The 52-week high of Smruthi Organics is ₹164.0 and the 52-week low is ₹95.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Smruthi Organics is ₹112 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Smruthi Organics Ltd is a average quality company.
The key valuation ratios of Smruthi Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Smruthi Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Smruthi Organics Ltd
Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products.
Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following:
- Process Development
- Process Optimization
- Process Validation
- Analytical Methods Validation
- Regulatory Support and DMF Registrations
- Commercial Manufacturing
Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.
Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.
Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.
Product range of the company includes:
API
- Amlodipine Base
- Amlodipine Besilate
- Carbidopa
- Carvedilol
- Chlorhexidine Base
- Chlorhexidine Salts
- Ciprofloxacin HCI
- Clofibrate
- Diloxanide Furoate
- Enrofloxacin
- Fenofibrate
- Fluconazole
- Iopomidol
- Metformin HCI
- Norfloxacin
- Pefloxacin
- S-Amlodipine
- Nabumetone
Drug Intermediate
- Nabumetone
- Iopamidol / Iohexol
- Montelukast
- Iopamidol
- Co-enzyme Q10
- Atorvastatin
- Carvedilol
- Ciprofloxacin/Enrofloxacin
- Perindopril
Achievements/ recognition:
- The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000.
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
